AlloSCT in TP53-mutated AML: from patient selection to post-transplant care
Pramila Krishnamurthy, MA, FRCPath, MRCP, PhD, King’s College Hospital NHS Foundation Trust, London, UK, presents the key considerations for allogeneic stem cell transplant (alloSCT) in patients with TP53-mutated acute myeloid leukemia (AML). Dr Krishnamurthy discusses patient selection, the use of genomics to refine prognosis, bridging therapies, and optimal conditioning studies and graft-versus-host disease (GvHD) prophylaxis. She also highlights post-transplant measurable residual disease (MRD) monitoring, maintenance, and donor lymphocyte infusion, as well as novel approaches such as the Phase I/II GRACE trial (NCT07372885). This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
